Acquired NF2 mutation confers resistance to TRK inhibition in an ex vivo LMNA::NTRK1‐rearranged soft‐tissue sarcoma cell model

• Published in: The Journal of pathology 2024-06, Vol.263 (2), p.257-269
• Main Authors: Chen, Yanjiang, Steiner, Sabrina, Hagedorn, Catherine, Kollar, Sarah, Pliego‐Mendieta, Alicia, Haberecker, Martina, Plock, Jan, Britschgi, Christian, Planas‐Paz, Lara, Pauli, Chantal
• Format: Article
• Language: English
• Subjects: acquired drug resistance; AKT protein; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Benzamides - pharmacology; Cell proliferation; Cloning; Drug development; Drug resistance; Drug Resistance, Neoplasm - genetics; Drug screening; Drug Synergism; ex vivo sarcoma cell model; Gene expression; Gene Rearrangement; Humans; Indazoles; Kinases; Lamin Type A - genetics; Lamin Type A - metabolism; LMNA::NTRK1‐rearranged soft‐tissue sarcoma; MAP kinase; Mutation; Neurofibromin 2; Neurofibromin 2 - genetics; Neurofibromin 2 - metabolism; Precision medicine; Protein Kinase Inhibitors - pharmacology; Protein-tyrosine kinase receptors; Pyridones - pharmacology; Pyrimidinones - pharmacology; Rapamycin; Receptor, trkA - antagonists & inhibitors; Receptor, trkA - genetics; Receptor, trkA - metabolism; Sarcoma; Sarcoma - drug therapy; Sarcoma - genetics; Sarcoma - metabolism; Sarcoma - pathology; Signal Transduction - drug effects; Sirolimus - pharmacology; Soft Tissue Neoplasms - drug therapy; Soft Tissue Neoplasms - genetics; Soft Tissue Neoplasms - pathology; targeted therapy; TOR protein; TRK inhibitor
• ISSN: 0022-3417; 1096-9896; 1096-9896
• DOI: 10.1002/path.6282

Genomic rearrangements of the neurotrophic receptor tyrosine kinase genes (NTRK1, NTRK2, and NTRK3) are the most common mechanism of oncogenic activation for this family of receptors, resulting in sustained cancer cell proliferation. Several targeted therapies have been approved for tumours harbouring NTRK fusions and a new generation of TRK inhibitors has already been developed due to acquired resistance. We established a patient‐derived LMNA::NTRK1‐rearranged soft‐tissue sarcoma cell model ex vivo with an acquired resistance to targeted TRK inhibition. Molecular profiling of the resistant clones revealed an acquired NF2 loss of function mutation that was absent in the parental cell model. Parental cells showed continuous sensitivity to TRK‐targeted treatment, whereas the resistant clones were insensitive. Furthermore, resistant clones showed upregulation of the MAPK and mTOR/AKT pathways in the gene expression based on RNA sequencing data and increased sensitivity to MEK and mTOR inhibitor therapy. Drug synergy was seen using trametinib and rapamycin in combination with entrectinib. Medium‐throughput drug screening further identified small compounds as potential drug candidates to overcome resistance as monotherapy or in combination with entrectinib. In summary, we developed a comprehensive model of drug resistance in an LMNA::NTRK1‐rearranged soft‐tissue sarcoma and have broadened the understanding of acquired drug resistance to targeted TRK therapy. Furthermore, we identified drug combinations and small compounds to overcome acquired drug resistance and potentially guide patient care in a functional precision oncology setting. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.